Analysis of serum to detect EGFR (epidermal growth factor receptor) mutations may be an alternative to using tumor tissue. Scorpion-ARMS was used to detect serum EGFR mutations in the single-arm Japanese JO22903 erlotinib study. Serum EGFR mutations (exon 19 deletions or L858R) were detected in 26.3% of patients analyzed; agreement between tumor and serum results was 96.2%. As sensitivity was low, further validation of serum-based EGFR analysis is needed. Background: Obtaining tumor samples for epidermal growth factor receptor (EGFR) mutation analysis during treatment can be difficult; therefore, serum samples may be a convenient alternative. We analyzed serum EGFR mutations in the Japanese phase 2 JO22903 study in chemotherapy-naive nonesmall-cell lung cancer patients with tumor EGFR mutations. Materials and Methods: Serum samples were analyzed by Scorpion-ARMS to detect EGFR mutations before and after erlotinib administration. Agreement between serum and tumor EGFR mutations and time course changes of EGFR mutations were evaluated. Results: A total of 95 of 103 patients consented to examination of serum samples; baseline serum EGFR mutations (exon 19 deletions or L858R) were detected in 25 patients (26.3%). The agreement rate between tumor and serum samples was 96.2%. Among 65 serum samples taken at 190 days after treatment initiation, EGFR mutations were detected in 5 patients (7.7%). Of the serum samples taken at progression (n ¼ 71), EGFR mutations were detected in 16 patients (22.5%). Patients with baseline serum EGFR mutations had a median progression-free survival of 9.7 months; those without baseline serum mutations had a median progressionfree survival of 15.2 months. Conclusion: The sensitivity of these analyses was not enough to draw firm conclusions; however, the results suggest that serum EGFR mutations correlate with disease activity.
Introduction
Nonesmall-cell lung cancer (NSCLC) remains a significant global health burden, with high mortality and poor prognosis for patients diagnosed at advanced stage. One treatment option is erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). The efficacy of erlotinib in the second-line setting was initially shown by the phase 3 BR.21 study. 1 In Japanese patients with previously treated disease, 2 phase 2 studies have also proven the efficacy and tolerability of erlotinib. 14.7 months, while Takahashi et al 3 reported time to progression of 75 days and median OS of 13.5 months. In the first-line EURTAC study of patients whose tumors harbored EGFR mutations, median PFS was 9.7 months and median OS was 19.3 months for erlotinib. 4 This led to erlotinib becoming the standard treatment for first-line EGFR mutationepositive NSCLC. The phase 2, single-arm JO22903 study of single-agent erlotinib was designed to obtain further confirmatory data for erlotinib in the first-line treatment setting for Japanese patients with EGFR mutationepositive NSCLC. The JO22903 primary efficacy results reported median PFS of 11.8 months, a 1-year event-free survival rate of 50%, and an overall response rate of 78%. 5 Confirmation of posttreatment EGFR mutation status is important to aid selection of optimal subsequent therapy after acquired resistance to erlotinib treatment. However, obtaining tumor samples can be difficult outside of surgical resection and initial biopsies, as nonsurgical methods often do not provide sufficient tumor DNA for analysis after treatment initiation. Therefore, plasma or serum samples may be more appropriate for further mutation testing in this setting, although sensitivity of this method must be considered. The Scorpion-ARMS method is one of the most sensitive methods for specific detection of mutations in DNA, as it enables single base mutations to be detected. 6, 7 A single base mismatch at the 3 0 end of the primer is sufficient for preferential amplification of the identically matched allele, allowing for precise discrimination between closely related sequences. Previous studies have already suggested the feasibility of using serum DNA to evaluate EGFR mutation status using the Scorpion-ARMS method in patients treated with gefitinib. 8, 9 This prespecified analysis measured EGFR mutations in serum samples before and after administration of erlotinib in the phase 2 JO22903 study compared the data with results from tumor samples in order to demonstrate a level of agreement and evaluated the time course changes of EGFR mutation type in serum samples.
Materials and Methods

Study Design
JO22903 was a phase 2, multicenter, open-label, nonrandomized study conducted at 25 centers in Japan. The detailed study design has been previously reported. 5 Eligible patients had advanced, untreated, metastatic (stage IIIB/IV) or relapsed NSCLC, with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 and tumors harboring confirmed activating mutations of EGFR (exon 19 deletion or L858R point mutation in exon 21). All patients provided written informed consent for this analysis.
Patients received oral erlotinib 150 mg per day until disease progression or unacceptable toxicity. Tumor EGFR mutation testing was carried out in local or central laboratories; Scorpion-ARMS methodology was used for testing in the central laboratory, while PNA LNA PCR-Clamp (42.7%), PCR-Invader (23.3%), Cycleave (17.5%), high-resolution melting analysis (5.8%), and direct sequencing (2.9%) were used in local laboratories, as methods that were used in daily practice at each site were selected. A high degree of agreement between these testing methodologies was observed. 5 
Serum Analysis
Serum samples were analyzed using Scorpion-ARMS methodology in the central laboratory. Serum was extracted from 3.5 mL of blood collected at baseline screening, on day 190 of treatment, and at disease progression (as judged by the investigator). DNA was extracted from 0.5 mL of serum using the QIAamp DNA MinElute Virus Spin Kit (Qiagen, UK) as per the manufacturer's instructions. EGFR gene mutations in DNA from serum were analyzed by Scorpion-ARMS using the EGFR RGQ PCR kit or Therascreen EGFR RGQ PCR kit (Qiagen, UK) as per the manufacturer's instructions. Scorpion-ARMS detected exon 19 deletions, L858R mutation, T790M mutation, L861Q mutation, G719X mutations, S768I mutation, and exon 20 insertions. The limits of detection for each mutation were as follows: exon 19 deletions (1.64%), L858R (1.26%), T790M (7.02%), L861Q (0.50%), G719X (5.43%), S768I (1.37%), and exon 20 insertions (2.03%).
This analysis evaluated agreement between EGFR mutations in serum and tumor tissue at screening and time course changes of EGFR mutation type in serum samples. The association between serum mutations and PFS outcomes was also evaluated.
Statistical Analyses
For PFS, which was assessed by investigators, median and 95% confidence limits were estimated by Kaplan-Meier methodology. Confidence interval (CI) limit was calculated according to the Greenwood method.
Results
Patient Population
Between April 8, 2010, and September 6, 2010, a total of 103 patients with confirmed EGFR mutations in tumor tissue were enrolled (n ¼ 50 with exon 19 deletions, n ¼ 51 with L858R mutations, n ¼ 2 with L858R þ T790M mutations). Serum EGFR mutations were determined at screening (n ¼ 95), day 190 of treatment (n ¼ 65), and at disease progression (n ¼ 71) (Figure 1) .
Baseline characteristics are shown in Table 1 . Overall, more female patients than male, more patients with ECOG PS 1 versus 0, and more patients with stage IV disease were enrolled.
Figure 1 CONSORT Diagram
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Comparison of EGFR Mutations in Serum and Tumor Tissue at Baseline Screening
Of the 95 patients with serum samples at baseline screening, 45 were identified as having exon 19 deletions by tumor sample analysis, and 50 were identified as having exon 21 L858R mutations. The detection rate of serum mutations identified as exon 19 deletions or L858R mutations before erlotinib treatment was 26.3% overall (25 of 95), with a detection rate of 35.6% for exon 19 deletions (16 of 45) and 18.0% for L858R mutations (9 of 50) ( Table 2) . One patient had an exon 20 S768I mutation, which is known as a minor mutation, detected in serum.
The agreement rate between serum and tumor tissue samples was 96.2% for patients whose serum status was detected (25 of 26). There was a 100% agreement rate between tumor and serum samples for exon 19 deletions and for exon 21 L858R mutations. The patient whose mutation status was discordant had target lesion tumors in the right middle lobe and left upper lobe of the lung and multiple nontarget lesions in the pleura. In this patient's sample, a S768l mutation was detected from the serum sample, but only the exon 19 deletion was detected from the tumor sample. T790M mutation or minor mutations other than S768l were not detected in any serum samples before erlotinib treatment.
Patients with serum EGFR mutations identified as exon 19 deletion or L858R mutation at baseline had a lower median age; there were also fewer patients with ECOG PS 0 and fewer never smokers than those patients without serum mutations at baseline ( Table 1) . Characteristics of patients with serum EGFR mutations detected at baseline were large number of organs with tumors or metastases and large tumor size. A total of 7.7% of patients who had one affected organ had serum EGFR mutations compared with 53.8% of those who had 4 affected organs and 75.0% of those with 6 affected organs ( Table 3 ). The mean number of affected organs for patients who had serum EGFR mutations was 3.80 (95% CI, 3.27-4.33) compared with 2.54 (95% CI, 2.26-2.82) for patients without serum EGFR mutations. Mutation detection rates by affected organ are shown in Supplemental Table 1 in the online version. A higher mutation detection rate was seen in patients whose sum of the longest diameter of target lesions was over 74 mm (40.0%) compared with those whose tumors were less than 26 mm in diameter (15.0%) ( Table 4 ). The mean sum of the longest diameter for patients who had serum EGFR mutations was 49.7 mm (95% CI, 40.9-58.5) compared with 68.1 mm (95% CI, 49.9-86.3) for patients without serum EGFR mutations. Median PFS for patients who had serum EGFR mutations at baseline was 9.7 months (95% CI, 5.5-12.3) compared with 15.2 months (95% CI, 9.7-17.9) for patients without serum EGFR mutations at baseline.
Time Course Determination of EGFR Mutations in Serum
At day 190 of erlotinib treatment, serum EGFR mutations were detected in only 5 patients (7.7%) out of the 65 with available samples. The 65 patients whose samples were available at day 190 had nonprogressive disease and were still receiving erlotinib treatment. Of the 5 patients with serum EGFR mutations, 4 patients had exon 19 deletions, while 1 had an L858R mutation.
At disease progression, serum EGFR mutations were detected in 16 (22.5%) of the 71 patients with available samples. This included 12 (57.1%) of the 21 patients with available samples whose serum EGFR mutations were detected at baseline. Of the 16 patients, 8 had exon 19 deletions (5 of these patients also had T790M mutations), while 8 had L858R mutations (2 of these patients also had T790M mutations) ( Table 5) .
Most of the patients had the same mutation in serum after treatment with erlotinib compared with baseline screening serum or Serum EGFR Mutations in Japanese NSCLC tumor samples; however, 2 patients had changed mutations from L858R mutations at baseline to exon 19 deletions at day 190. One patient had target lesion tumors in the right upper lobe of the lung and in the lymph nodes, with brain (multiple lesions), bone (multiple lesions), and pericardial effusion as nontarget lesions. Target lesions were decreased with erlotinib treatment (partial response) but progressed at day 335. Bone and brain metastases as nontarget lesions did not change during the treatment period, and pleural effusion as nontarget lesions disappeared; however, new lesions were found. The other patient had tumors in the right middle lobe of the lung and in the lymph nodes as target lesions, with brain (multiple lesions) and bone (multiple lesions) as nontarget lesions. Target lesions were decreased (partial response), and brain metastases as nontarget lesions did not change as of day 210; however, bone metastases as nontarget lesions progressed at day 245, and a new lesion was found in bone TH3 at day 245. T790M mutation was detected in serum for 7 patients. Serum sample collection day for each of these patients was 167, 252, 266, 358, 382, 547, and 609 days after the start of erlotinib, respectively.
Discussion
Obtaining tumor samples can be difficult outside of surgical resection and initial biopsies, as nonsurgical methods often do not provide sufficient tumor DNA for analysis after treatment initiation. Therefore, plasma or serum samples may be more appropriate for posttreatment EGFR mutation testing if agreement with tumor samples can be demonstrated.
In the JO22903 study, although the agreement rate between serum and tumor tissue samples at baseline screening was high (96.2%), detection sensitivity was low (mutation detection rate in serum samples before initiation of erlotinib treatment was 35.6% for exon 19 deletions [16 of 45] and 18.0% for L858R mutations [9 of 50]). The detection rate in serum appeared better for exon 19 deletions compared with L858R mutations; however, the reasons behind this are unclear. This could be due to the heterogeneous nature of tumor biology or due to the assay itself. Some reports suggested that there is a difference in phenotype between L858R and exon 19 deletion, which could be related to this difference. 10, 11 Further investigation is needed to optimize this method of mutation identification.
The detection sensitivity in serum has varied among previous studies. Bai et al 12 reported a sensitivity of 81.8% using a denaturing high-performance liquid chromatography detection technique in Chinese patients with advanced NSCLC treated with firstline chemotherapy. Rosell et al 13 showed sensitivity of 59.1% using both direct sequencing and allele-specific detection techniques in Spanish patients treated with first-or second-line erlotinib. Sensitivity of 75.0% was shown by Kimura et al 8 using Scorpion-ARMS with patients treated with first-, second-, or third-line gefitinib. Goto et al 9 reported sensitivity of 43.1% using Scorpion-ARMS in a Japanese NSCLC population treated with first-line gefitinib. The reason why this JO22903 analysis showed the lowest sensitivity among previous studies is unclear. One possibility is that the variance of sensitivity between studies may be attributed to the different methods of extraction, detection, and run conditions. Previously, these studies showed that improvement in detection sensitivity would be needed for use in daily clinical practice at this time. Interestingly, Mok et al 14 have recently shown promising data using a new polymerase chain reaction (PCR)-based method optimized for blood screening in the FASTACT-2 study, in which sensitivity was 75% and concordance was 88% using the Cobas 4800 blood test (in development). Overall, these studies concluded that the detection of EGFR mutations in serum or plasma could be feasible, and further investigation is warranted. Characteristics of patients with serum EGFR mutations in pretreatment samples were large number of affected organs and large sum of longest diameter of target lesion. This may be explained by those patients with an increased tumor burden having more cells or DNA to leak into the serum as circulating tumor cells, therefore resulting in more successful detection of mutations as more cells are present to analyze. This may also explain why a higher mutation detection rate was seen in patients with ECOG PS 1 compared with PS 0 (34.0% vs. 17.8%, respectively), as those with PS 1 would typically have a higher tumor load, therefore shedding more cells into serum for analysis. Median PFS for patients with serum EGFR mutations was shorter than for those without serum EGFR mutations. This again could be attributed to these patients having a larger number of affected organs, as tumor distribution is a critical factor in progression and survival.
At day 190 of erlotinib treatment, serum EGFR mutations were detected in only 5 patients, whereas at disease progression serum EGFR mutations were detected in 16 patients. This could be explained by the changing tumor burden, as during treatment (day 190) the tumor burden may have decreased from that seen at 
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Clinical Lung Cancer January 2016 -27 baseline, therefore resulting in fewer cells leaking into the serum, leading to a lower mutation detection rate. At disease progression, when a patient has an increased tumor burden, more cells are present in the serum again, allowing for a higher mutation detection rate. Although some previous studies showed the correlations between clinical characteristics and EGFR mutation status detected from blood samples, 8, 9, [12] [13] [14] no studies have reported a correlation with tumor burden. Meanwhile, Mok et al 14 demonstrated the change of EGFR mutation status throughout the course of erlotinib treatment and the detection rate was lower in the middle of treatment than at baseline or after progression disease, which is consistent with our data. The T790M mutation was not detected in any serum samples before erlotinib treatment, and was only seen in serum samples at disease progression not at day 190. This may be because this mutation is more prevalent in tumors after initial treatment. T790M cells are resistant to erlotinib; therefore, during treatment, other cells that are not resistant are depleted, meaning that T790M cells are enriched and are more likely to be identified at this time point. T790M mutation was not detected at disease progression in 3 patients who had progression disease early (< 100 days) without tumor response, which suggested that these patients had resistance factor other than T790M mutation. Oxnard et al 15 showed that acquired T790M mutation has been associated with indolent growth compared with T790M-negative acquired resistance, which is consistent with the results of JO22903. These data suggest that the time to onset of resistance is different depending on the mechanism of resistance. The T790M mutation is known to have poor sensitivity to EGFR TKIs and has been suggested as one of the major reasons for EGFR TKI treatment failure; thus, T790M mutant-selective covalent inhibitors or other novel agents would be beneficial for patients with the acquired T790M mutation. However, EGFR TKIs might still be effective for some patients with acquired resistance other than T790M, and EGFR TKI readministration or continuation would be possible treatment options for those patients. Although the overall detection sensitivity was only 22.5% (16 of 71) at disease progression, serum EGFR mutations were able to be detected in 57.1% of patients whose serum EGFR mutations were detected at baseline. Also, the T790M mutation was detected at the time of disease progression by Scorpion-ARMS, which can be used in clinical practice. These data suggest that serum EGFR mutations monitoring during treatment may be useful if serum EGFR mutations are detected at baseline. To obtain useful information for optimal treatment selection in every patient with EGFR TKI resistance, improved sensitivity methods with plasma or serum are required. Most of the patients had the same mutations in serum after treatment with erlotinib compared with the baseline screening serum and tumor samples. Two patients had changed mutations; however, these patients also had multiple metastases. This change in mutation could be due to the heterogeneous nature of NSCLC between primary and metastatic tumors; however, the causality of these mutation changes is not fully understood and could warrant further investigation.
Conclusion
Detection of EGFR mutations from serum samples provided insufficient accuracy in this study; this method needs to be improved in order to obtain further confirmatory results. Mutationpositive serum samples provided a 96.2% agreement rate with tumor mutation analysis. The data also suggest that the changing time course of serum EGFR mutations could correlate with disease activity. Serum EGFR mutation detection during treatment course Serum EGFR Mutations in Japanese NSCLC could give useful information for subsequent treatment selection, especially in situations where obtaining tumor samples is difficult; however, further investigation is needed.
Clinical Practice Points
Obtaining tumor samples for assessment of EGFR mutation status can be difficult in some cases; therefore, a less invasive method to acquire samples for mutation detection would be beneficial. Blood-based samples (either plasma or serum) have recently been investigated in a number of studies using various techniques including Scorpion-ARMS, denaturing high-performance liquid chromatography, peptide nucleic acidemediated PCR, and digital droplet PCR. Although detection rates vary between the different methods, the overall consensus is that blood-based analysis is feasible. The JO22903 study used Scorpion-ARMS technology to assess EGFR mutations in serum samples in Japanese patients treated with erlotinib. Baseline serum EGFR mutations were detected in 25 patients (26.3%). The agreement rate between tumor and serum samples was 96.2%. Patients with baseline serum EGFR mutations had median PFS of 9.7 months; those without baseline serum mutations had median PFS of 15.2 months. The sensitivity was low for the detection of EGFR mutations from serum in JO22903, which highlights that further validation of the optimal method for blood-based assessment is needed, including comparing serum versus plasma samples in addition to different assessment methodologies. The JO22903 results suggested that the changing time course of serum EGFR mutations could correlate with disease activity. This is an aspect that, once further validated, could provide an alternative to the Response Evaluation Criteria in Solid Tumors for assessing disease progression. Validation of a blood-based assessment method will allow patients who are currently unable to undergo tissue-based mutation testing to get tested, resulting in better guidance for treatment decisions.
